Every 8-K that OSR HEALTH INC (OSRH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow OSRH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OSRH filings page.
OSR Health, Inc. (OSRH) reports that a Nasdaq Hearings Panel has scheduled a hearing for September 29, 2026 at 10:00 a.m. Eastern Time regarding the company’s appeal of a Nasdaq staff determination to delist its securities. A timely hearing request was submitted on August 25, 2026, which stayed the filing of a Form 25-NSE and therefore the formal delisting from Nasdaq, but did not prevent the suspension of trading in OSR Health’s securities that took effect at the opening of business on August 26, 2026. The company is preparing a comprehensive plan to regain and sustain compliance with Nasdaq’s continued listing requirements and intends to advocate for continued listing, while cautioning that there can be no assurance the Panel will grant its request or that compliance will be regained.
OSR Health, Inc. (OSRH) reports an update on its Nasdaq listing status. Nasdaq staff previously determined to delist the company’s common stock and warrants from the Nasdaq Capital Market for non-compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). On August 25, 2026, OSR Health requested a hearing before a Nasdaq Hearings Panel to appeal the delisting determination and asked for continued listing of its securities. The company states that trading in its securities is still scheduled to be suspended at the opening of business on August 26, 2026, despite the hearing request. The hearing request is expected to stay the filing of a Form 25-NSE, delaying formal delisting and deregistration while the Panel reviews the case. OSR Health plans to present a compliance plan but cautions there is no assurance the Panel will grant continued listing or that it will regain compliance.
OSR Health, Inc. (symbol OSRH) disclosed that Nasdaq has issued a Staff Determination to delist its common stock and warrants from the Nasdaq Capital Market for failure to meet the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). Nasdaq plans to suspend trading in OSRH common stock and warrants at the opening of business on August 26, 2026, and to file a Form 25-NSE to remove the securities from listing and registration.
The company intends to request a hearing before a Nasdaq Independent Hearings Panel under the Nasdaq Listing Rule 5800 Series. A timely hearing request is expected to stay the filing of the Form 25-NSE, but will not stay the trading suspension. OSR Health highlights recent trading activity, including approximately 370 million and 145 million shares traded on August 17 and 18, 2026, respectively, versus a public float of about 18.5 million shares, and notes its share price reached an intraday high of $0.84 on August 18, still short of the $1.00 compliance level.
OSR Health, Inc. reported results of its August 7, 2026 annual stockholder meeting. As of the July 8, 2026 record date, there were 35,118,692 common shares outstanding. A total of 21,088,120 shares, or 60.05% of shares entitled to vote, were represented, constituting a quorum.
Stockholders re-elected seven directors to serve until the 2027 annual meeting, with each nominee receiving more than 15.17 million votes “for” and roughly 0.12–0.13 million votes “withheld.” Stockholders also approved ratification of the independent auditor with 20,296,535 votes “for,” the advisory executive compensation proposal with 15,059,135 votes “for,” and an Authorized Shares Increase Proposal with 19,922,498 votes “for” versus 581,009 “against.”
OSR Health, Inc. issued a clarification about earlier statements describing Nasdaq’s views on its Shareholder Loyalty Contingent Value Rights (CVR) program. The company explained that language in its July 31, 2026 release should not be read as implying Nasdaq has approved or endorsed the CVR program.
OSR Health stated that Nasdaq’s prior feedback was a preliminary, verbal response limited to a technical question about whether the CVR program would trigger a mechanical stock price adjustment, such as an ex-date adjustment, and that Nasdaq has expressed no definitive opinion on the program more broadly. The clarification confirms that the previously announced August 14, 2026 record date for the Shareholder Loyalty CVR program remains unchanged.
OSR Health, Inc. reported that Nasdaq, in a verbal communication, stated the company’s Shareholder Loyalty Contingent Value Rights (CVR) program will not cause any mechanical adjustment to the price of its common stock, either when CVRs are distributed or when additional shares are delivered to enrolled holders.
Under this loyalty CVR program, shareholders of record on August 14, 2026 who enroll receive one CVR for each share of OSRH common stock and may receive additional shares at no cost if specified closing-price thresholds are met on four measurement dates over the following twelve months. Nasdaq’s view applies only to price-adjustment mechanics and is not an endorsement; the CVR distribution and share deliveries remain subject to separate securities-law and regulatory processes.
OSR Health, Inc., formerly OSR Holdings, Inc., has changed its corporate name to OSR Health, Inc. effective June 11, 2026. The change was approved by the board of directors and implemented through a Certificate of Revival of Charter filed under Delaware corporate law.
The filing of the Certificate of Revival renewed and revived the company’s certificate of incorporation, and the company is in good standing with the Delaware Secretary of State. No other provisions of the certificate of incorporation were amended, and the terms of the common stock and redeemable warrants remain unchanged.
The company’s common stock and warrants continue to trade on The Nasdaq Stock Market LLC under the symbols OSRH and OSRHW, respectively. Stockholders and warrant holders do not need to exchange or surrender existing certificates as a result of the name change.
OSR Holdings, Inc. has postponed its 2026 Annual Meeting of Stockholders. The meeting had been scheduled for June 18, 2026, but the Board decided on June 5, 2026, that more time is needed to evaluate matters related to the meeting and the business to be presented.
The company has not set a new date and plans to announce the rescheduled date, time, and related details in a later SEC filing and other communications. A definitive proxy statement for the meeting has already been filed, and stockholders are encouraged to review the proxy materials available on the SEC’s website and the company’s site.
OSR Holdings, Inc. reported that it entered into an Asset Purchase Agreement with its indirect subsidiary Vaximm AG on May 27, 2026. The deal is a related party transaction and is designed to transfer outright ownership of intellectual property related to Vaximm’s programs from Vaximm to OSR Holdings.
This transfer aligns with a previously executed Global Exclusive License Agreement among OSR Holdings, Vaximm and BCM Europe AG covering VXM01, an oral DNA-based cancer immunotherapy. After the transfer, OSR Holdings will directly hold the underlying intellectual property and be the direct beneficiary of any future milestone and royalty payments arising from the license. The agreement includes customary representations, covenants, indemnification and confidentiality terms and is governed by Swiss law.
OSR Holdings, Inc. filed an amended current report to add an independent fairness opinion on its related-party Global Exclusive License Agreement for cancer immunotherapy asset VXM01 with BCM Europe. The opinion concludes that up to $815 million in clinical, regulatory, and commercial milestones plus royalties are financially fair to OSR, Vaximm, and unaffiliated shareholders, based on a Monte Carlo median standalone asset value of about $93.4 million and a 40/60 licensor–licensee value split. The structure includes a 15% preferred return on any milestone shortfall recovered from downstream royalties, an option for OSR to issue up to $15 million of stock at $10.00 per share, and full pass-through of royalties after recovery. A contemplated blockchain-based TAC token royalty mechanism is explicitly excluded from the fairness conclusion.
OSR Holdings, Inc. entered a definitive global exclusive license agreement with its largest shareholder, BCM Europe AG, for VXM01, a Phase 3-ready oral immunotherapy targeting VEGFR-2. The structure includes potential milestone obligations of up to $815 million tied to VXM01’s development and commercialization.
To secure these obligations, BCM Europe and affiliates signed a Pledge Agreement, pledging their entire unencumbered OSR Holdings stake, representing about 29.7% of shares as of signing, as collateral. The deal also grants OSR Holdings a put option to require BCM Europe to buy up to $15 million of common stock at $10.00 per share, exercisable no earlier than six months after the agreement takes effect. The transaction is a related party deal and was approved by the Board, including independent directors, after an independent fairness opinion.
OSR Holdings, Inc. appointed Yeiseok Kim as Chief Operating Officer, effective April 16, 2026. The Board approved his appointment on March 26, 2026, and an amended employment agreement provides for increased annual compensation.
Kim, age 36, previously served as a Senior Analyst at OSR Holdings Co., Ltd. from 2020 to 2025, supporting cross-border healthcare investments and pharmaceutical licensing. He holds a BA in Environmental Science from Seoul National University and an MS in Medicine from Jeonbuk National University, along with a Korean medical license obtained in 2019.
The company notes there are no special arrangements or understandings behind his appointment, no family relationships with directors or executives, and no related-party transactions requiring disclosure under Item 404(a) of Regulation S-K.
OSR Holdings, Inc. entered into a second amendment to its equity line with White Lion GBM Innovation Fund, adding new intraday and fixed purchase mechanisms that let the company sell stock at 90% of the volume-weighted average price over defined trading periods, with threshold-price protections for certain purchases.
The company also agreed to issue a senior secured convertible promissory note with a principal amount of $1,055,555.55 to White Lion. OSR Holdings received $500,000 in cash and reduced approximately $2,019,290 of amounts outstanding under an existing warrant, effectively cancelling that warrant.
The note bears 5% annual interest, matures in nine months, and is initially convertible at the holder’s option at a $1.00 per share fixed price, with certain market-based conversion alternatives. Conversion generally cannot begin until six months after issuance and is limited by a 4.99% beneficial ownership cap, which White Lion may increase to 9.99%. The note is a senior secured obligation, backed by substantially all company assets, and was issued in a private placement relying on Securities Act exemptions.
OSR Holdings, Inc. filed an amended current report to correct an exhibit attached to a prior disclosure. The amendment replaces Exhibit 10.1 with a corrected version of the Global License Agreement for VXM01, dated March 23, 2026, among Vaximm AG, OSR Holdings, Inc. and BCM Europe AG. The update is described as fixing clerical errors, including the stated per share price, and does not change any other information contained in the original report.
OSR Holdings, Inc. entered into a binding term sheet with BCM Europe AG for a revised global exclusive license of VXM01, with OSR Holdings added as a direct counterparty and primary recipient of economics.
Upon a definitive license agreement, Vaximm AG will grant BCME an exclusive, worldwide, sublicensable license to develop and commercialize VXM01. BCME will be responsible for up to $815.0 million in milestone payments payable directly to OSR Holdings, while OSR Holdings will provide Vaximm with a development financing facility of up to $30.0 million. Closing of a definitive agreement is subject to due diligence, board approvals, and an independent fairness opinion.
OSR Holdings, Inc. furnished an update to ensure fair disclosure after inadvertently sharing non‑public information with a sell‑side analyst about its drug development subsidiary, Vaximm AG, and SillaJen, Inc.
Vaximm is in active, but non‑binding, negotiations with SillaJen over a potential licensing arrangement for Pexa‑Vec, an oncolytic immunotherapy in a Phase 2 FDA‑regulated study for renal cell carcinoma. Separately, OSR Holdings’ management has held very early, exploratory verbal discussions about potentially acquiring a controlling interest in SillaJen representing approximately 16% of its outstanding common shares. No term sheet, structure, financing, or definitive agreements exist for either the licensing or equity transaction, and the company stresses there is no assurance any deal will be completed. OSR Holdings indicates it does not plan further updates unless later developments independently require disclosure.
OSR Holdings, Inc. received notice from Nasdaq that it has been granted an additional 180-day period, until August 31, 2026, to regain compliance with the Nasdaq minimum bid price rule requiring a bid of at least $1.00 per share.
The company was first notified on September 5, 2025, that its stock had traded below $1.00 for 30 consecutive business days and initially had until March 4, 2026, to regain compliance. Nasdaq granted more time because OSR Holdings meets all other Nasdaq Capital Market listing standards, including market value of publicly held shares.
If the closing bid price is at least $1.00 per share for a minimum of 10 consecutive business days during this new period, Nasdaq will confirm that the company has regained compliance. OSR Holdings plans to monitor its share price and consider available options to meet Nasdaq’s bid price requirement.
OSR Holdings, Inc. completed the acquisition of South Korea-based medical device company Woori IO Co., Ltd. (WORIO) on January 26, 2026 through a share exchange under the Korean Commercial Act. OSR Holdings’ subsidiary OSR Holdings Co., Ltd. (OSRK) acquired all issued and outstanding WORIO shares, making WORIO a wholly owned subsidiary of OSRK and an indirect subsidiary of OSR Holdings.
Each WORIO share was exchanged for 0.948832 OSRK shares, and OSRK issued an aggregate of 84,338 new shares in exchange for 88,891 WORIO shares. The transaction was completed using equity in the subsidiary, and no OSR Holdings common stock was issued. OSR Holdings plans to file any required financial statements for this acquisition by amendment within 71 days.
OSR Holdings, Inc. reported that its wholly owned subsidiary Vaximm AG signed a binding term sheet with BCM Europe AG for a proposed global exclusive license of the VXM01 oral cancer immunotherapy platform. Under the term sheet, once a definitive global license agreement is executed, BCM Europe AG would pay Vaximm an upfront payment of $30.0 million, split between $15.0 million in cash and $15.0 million in digital assets, plus up to $815.0 million in potential clinical, regulatory, and commercial milestone payments.
The term sheet includes binding provisions on the license grant, financial terms, and exclusivity, while the final agreement is still subject to customary conditions, including an independent third-party fairness opinion. The company also furnished a press release describing the binding term sheet and the proposed VXM01 license arrangement.
OSR Holdings, Inc. (OSRH) reported that its Swiss-based subsidiary, Vaximm AG, has signed a non-binding global license agreement term sheet with BCM Europe AG, the company’s largest shareholder. The term sheet covers the potential global license of Vaximm’s VXM01 oral cancer immunotherapy platform and includes an exclusivity period for negotiations and certain binding provisions.
According to the related press release, the contemplated license could provide $20 million upfront and up to $815 million in milestone payments, if a definitive agreement is ultimately signed and completed. The current term sheet itself is not a final contract and does not yet impose material obligations on OSR Holdings.
OSR Holdings Inc. (NASDAQ: OSRH) announced a definitive Share Exchange Agreement for its subsidiary OSR Holdings Co., Ltd. to acquire all shares of Woori IO Co., Ltd., a South Korea-based developer of non-invasive glucose monitoring using NIRS technology. Each Woori IO share will be exchanged for 0.948832 OSRK shares, with OSRK issuing 84,338 new shares for 88,891 Woori IO shares. The aggregate transaction value is approximately KRW 15 billion (USD 10.6 million).
Woori IO has been providing technical development services to Samsung Electronics under a proof-of-concept agreement funded on a non-dilutive basis. Closing is subject to customary conditions, including Woori IO shareholder approval (target meeting date December 19, 2025) and regulatory clearances, with an expected effective date of January 12, 2026.
Per Annex 2, within three years after closing, if OSRH common stock reaches USD 10.00 per share on Nasdaq, OSRK shares received by former Woori IO holders may be exchangeable into OSR Holdings Inc. common stock at 12.96 OSRH per OSRK share, subject to applicable U.S. securities laws and Board approval.
OSR Holdings, Inc. filed an 8-K reporting the results of a shareholder vote on director elections. Several nominees received overwhelming affirmative votes and were elected, while two nominees received large negative vote totals and were not elected. For example, Jun Chul Whang received 13,321,765 votes for and 3,926 against and was elected. Seng Chin Mah received 13,321,806 for and 3,885 against and was elected. Two nominees, Jin Whan Park (451,054 for; 12,874,637 against) and Phil Geon Lee (451,095 for; 12,874,596 against), were not elected. The filing supplies vote counts and final election outcomes for each listed nominee.
OSR Holdings, Inc. reported that it received a Nasdaq notice on September 5, 2025 stating its common stock no longer meets the exchange’s minimum bid price rule, which requires a closing bid of at least $1.00 per share for 30 consecutive business days. The company’s stock traded below this level for that full period, triggering the deficiency.
The notice does not immediately affect trading, and OSR Holdings’ common stock and warrants will continue to trade on the Nasdaq Capital Market under the symbols OSRH and OSRHW. The company has 180 calendar days, until March 4, 2026, to regain compliance by maintaining a closing bid price of $1.00 or more for at least ten consecutive business days.
If OSR Holdings does not regain compliance by March 4, 2026, it may qualify for an additional 180‑day period if it meets other Nasdaq listing standards and formally notifies Nasdaq of its plan to cure the deficiency, potentially including a reverse stock split. If it cannot secure the extra period or still fails to comply, its securities could be delisted, a decision the company would have the right to appeal. The company states it will monitor its share price and consider options to restore compliance.
OSR Holdings, Inc. entered into two amendments with White Lion Capital, LLC on August 10, 2025, tied to its existing financing arrangements. The company agreed in an amendment to its Note Purchase Agreement to take all necessary actions to convene a stockholder meeting before September 19, 2025 to seek approval for all transactions with White Lion, including issuing securities above the 19.99% Nasdaq Rule 5635 exchange cap and matters under the Equity Line of Credit Agreement dated February 25, 2025. If the company fails to take these actions, it would be in material breach and owe $400,000 in liquidated damages, payable immediately in cash, although simply failing to obtain stockholder approval would not be a breach if the required actions were taken. A parallel amendment to the Common Stock Purchase Warrant clarifies exchange cap provisions and aligns the warrant terms with the note agreement and the equity line.
OSR Holdings, Inc. (Nasdaq: OSRH) filed a Form 8-K to disclose that independent director Sang Hyun Kim resigned from the Board of Directors effective June 26 2025. The company states the resignation "was not the result of any dispute or disagreement" concerning its operations, policies, or practices. No other management changes, financial results, or strategic actions were reported.
- Event date: June 26 2025 (reported July 2 2025)
- Affected position: Independent director seat now vacant
- Reason given: Personal resignation, no disputes cited
No compensatory arrangements, replacement plans, or additional board changes were included in the filing.